DOCSLIB.ORG

Evaluation of the Aldose Reductase Inhibitor Fidarestat on Ischemia-Reperfusion Injury in Rat Retina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evaluation of the Aldose Reductase Inhibitor Fidarestat on Ischemia-Reperfusion Injury in Rat Retina 135-142.qxd 20/5/2010 10:19 Ì ™ÂÏ›‰·135 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 26: 135-142, 2010 135 Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina IRINA G. OBROSOVA1, YURY MAKSIMCHYK1, PAL PACHER2, ELISABET AGARDH4, MAJ-LIS SMITH4, AZZA B. EL-REMESSY3 and CARL-DAVID AGARDH4 1Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA; 2Section on Oxidative Stress Tissue Injury, Laboratory of Physiological Studies, NIH/NIAAA, Bethesda, MD; 3Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, USA; 4The Department of Clinical Sciences, University Hospital MAS, Lund University, Malmö, Sweden Received February 24, 2010; Accepted March 29, 2010 DOI: 10.3892/ijmm_00000445 Abstract. This study evaluated the effects of retinal ischemia- intermediate accumulation. These changes were prevented or reperfusion (IR) injury and pre-treatment with the potent and alleviated by the AR inhibitor fidarestat. The results identify specific aldose reductase inhibitor fidarestat on apoptosis, AR as an important therapeutic target for diseases involving aldose reductase and sorbitol dehydrogenase expression, sorbitol IR injury, and provide the rationale for development of pathway intermediate concentrations, and oxidative-nitrosative fidarestat and other AR inhibitors. stress. Female Wistar rats were pre-treated with either vehicle (N-methyl-D-glucamine) or fidarestat, 32 mgkg-1d-1 for both, Introduction in the right jugular vein, for 3 consecutive days. A group of vehicle- and fidarestat-treated rats were subjected to 45-min Sorbitol pathway of glucose metabolism consists of two retinal ischemia followed by 24-h reperfusion. Ischemia was reactions, aldose reductase (AR)-catalyzed NADPH-dependent induced 30 min after the last vehicle or fidarestat adminis- reduction of glucose to its sugar alcohol, sorbitol, followed tration. Retinal IR resulted in a remarkable increase in retinal by sorbitol dehydrogenase(SDH)-catalyzed NAD-dependent cell death. The number of TUNEL-positive nuclei increased oxidation of sorbitol to fructose. For almost 50 years after its 48-fold in the IR group compared with non-ischemic controls discovery (1), it has been considered that activation of the (p<0.01), and this increase was partially prevented by fidarestat. sorbitol pathway of glucose metabolism is a direct consequence AR expression (Western blot analysis) increased by 19% in of hyperglycemia or hypergalactosemia. This notion has been the IR group (p<0.05), and this increase was prevented by supported by numerous studies with AR inhibitors in animal fidarestat. Sorbitol dehydrogenase and nitrated protein expres- models of diabetes and galactose feeding which provided sions were similar among all experimental groups. Retinal evidence for the important role of increased sorbitol pathway sorbitol concentrations tended to increase in the IR group activity in diabetic or diabetes-like complications including but the difference with non-ischemic controls did not achieve cataract (2-4), retinopathy (2,5,6), peripheral and autonomic statistical significance (p=0.08). Retinal fructose concen- neuropathy (7-11), and nephropathy (12,13). The important trations were 2.2-fold greater in the IR group than in the non- role for the first enzyme of the sorbitol pathway, AR, in several ischemic controls (p<0.05). Fidarestat pre-treatment of rats diabetic complications has further been confirmed in studies subjected to IR reduced retinal sorbitol concentration to the with AR-overexpressing and AR-knockout mice (14-17). levels in non-ischemic controls. Retinal fructose concentrations Recent reports suggest that increased sorbitol pathway were reduced by 41% in fidarestat-pre-treated IR group vs. activity is also involved in the pathogenesis of diseases that untreated ischemic controls (p=0.0517), but remained 30% are not accompanied by hyperglycemia including atheroscle- higher than in the non-ischemic control group. In conclusion, rosis (18), cancer (19), and a number of inflammatory condi- IR injury to rat retina is associated with a dramatic increase tions and disorders such polymicrobial sepsis (20), asthma (21) in cell death, elevated AR expression and sorbitol pathway and uveitis (22). Evidence for the important role of this mecha- nism in ischemia-reperfusion (IR) injury, and, in particular, _________________________________________ in cardiac (23-25) and, recently, retinal (26,27) IR injury is Correspondence to: Dr Irina G. Obrosova, Pennington Biomedical emerging. Research Center, Louisiana State University System, 6400 Perkins In human disease, retinal IR injury takes place when retinal Road, Baton Rouge, LA 70808, USA blood flow is interrupted for a long period of time and then E-mail: [email protected] restarted. It occurs in transient ischemia-related diseases, such as central retinal artery occlusion, angle-closure glaucoma, Key words: aldose reductase, apoptosis, fidarestat, nitrated proteins, amaurosis fugax, as well as in diabetes, atherosclerosis, and retinal ischemia-reperfusion, sorbitol dehydrogenase hypertension (26-29). Retinal ischemia and diabetic retino- pathy share many pathophysiological and pathological features 135-142.qxd 20/5/2010 10:19 Ì ™ÂÏ›‰·136 136 OBROSOVA et al: FIDARESTAT ALLEVIATES RETINAL ISCHEMIA-REPERFUSION INJURY including but not limited to b-wave abnormalities in the jugular vein was exposed and catheterized to allow repeated electroretinogram (30,31), glial activation (32,33), retinal i.v. injections. The catheter was tunneled under the skin to neuronal and ganglion cell degeneration (26,34), increased appear through a small cut in the neck scruff. After injection, vascular permeability and breakdown of blood-retinal barrier the catheter was closed and replaced under the skin and (35,36), edema (26,37), capillary cell loss (38,39), and accele- wounds were sutured. Injections were repeated on day 2 under rated angiogenesis (40,41). Also note, that whereas retinal 2% isoflurane anesthesia. On day 3, the animals were anes- ischemia plays an important role in the progression of diabetic thetized with fentanyl (300 μg/kg i.p., B. Braun, Melsungen, retinopathy towards its advanced, or proliferative stage (41), Germany) followed by medetomidin (300 μg/kg i.p., Domitor its treatment with scatter laser photocoagulation restoring Vet, Orion Pharma Animal Health, Sollentuna, Sweden), and oxygen supply is associated with the development of sight- a third dose of fidarestat or NMDG was given 30 min before threatening macular edema (42). Sixty percent of eyes treated induction of ischemia. with scatter photocoagulation showed an increase in foveal thickness, detectable by a scanning retinal thickness analyzer, Induction of ischemia and reperfusion. The pupils were dilated after photocoagulation (42). with cyclopentolate 1% (Cyclogyl®, Alcon, Stockholm, A recent study in AR-deficient mouse model implicated Sweden) followed by the application of a local anesthetic, increased AR activity in neuronal loss and edema associated tetracaine 1% (Tetrakain Chauvin, Novartis Ophthalmic, with retinal IR injury (26). In the same report, IR-associated Copenhagen, Denmark) which allowed the direct observation increase in TUNEL positivity in retinal ganglion cell and inner of retinal blood flow under a stereomicroscope. Retinal neuronal layers, retinal thickening, as well as cytoarchitectural ischemia was induced 30 min after the vehicle or fidarestat disorganization were prevented or markedly reduced by the injection, by careful application of a 5-0 silk suture (Ethicon, ARI fidarestat. In our recent experiments in the rat model of Sollentuna, Sweden) around the vessels and the accom- retinal IR injury, pre-treatment with fidarestat alleviated panying optic nerve of the left eye as described (43). The inflammatory response (27). The present study conducted in ligature was tightened until complete cessation of the retinal the same animal model evaluated the effects of IR injury and blood flow occurred. The right eye served as a non-ischemic fidarestat pre-treatment on retinal apoptosis, AR and sorbitol control. During induction of ischemia, rats were placed in dehydrogenase (SDH) protein expressions, sorbitol pathway cages supplied with a heating pad, to avoid a decrease in intermediate concentrations, and oxidative-nitrosative stress. body temperature. After 45 min, the ligature was carefully removed. After confirmation of restoration of retinal blood Materials and methods flow, anesthesia was reversed by bupenorfin (30 μg/kg s.c., Temgesic®, Schering-Plough, Kenilworth, NJ, USA) and Reagents. Unless otherwise stated, all chemicals were of atipamezol (1 mg/kg s.c., Antisedan Vet, Orion Pharma Animal reagent-grade quality, and were purchased from Sigma Health, Sollentuna, Sweden), and reperfusion continued for Chemical Co., St. Louis, MO. Rabbit polyclonal anti- 24 h, after which all animals were sacrificed. nitrotyrosine antibody was purchased from Upstate, Lake Placid, NY, USA. Mouse anti-AR monoclonal antibody was Euthanasia and retinal dissection. The rats were sedated by purchased from Santa Cruz Biotechnology, Santa Cruz, CA, CO2, and were immediately sacrificed by cervical dislocation. USA. Mouse anti-SDH monoclonal antibody was obtained In approximately half of animals in each experimental group, from Abcam, Cambridge, MA, USA. ApopTag® Peroxidase both eyes were rapidly enucleated, the lenses were removed, In Situ
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • IP Vol.2 No.2 Jul-Dec 2014.Pmd
    International Physiology63 Short Communication Vol. 2 No. 2, July - December 2014 Role of Polyol Pathway in Pathophysiology of Diabetic Peripheral Neuropathy: An Updated Overview Kumar Senthil P.*, Adhikari Prabha**, Jeganathan*** Abstract The aim of this short communication article was to enlighten the role of polyol pathway in pathophysiology of diabetic peripheral neuropathy (DPN) through an evidence-informed overview of current literature. Findings from experimental models of DPN suggest that altered glutathione redox state, with exaggerated NA(+)-K(+)-ATPase activity, increased malondialdehyde content, decreased red blood cell 2,3-diphosphoglycerate concentration, reduced cyclic adenosine monophosphate, reduced myo- inositol and excessive sorbitol in peripheral nerves were indicative of polyol metabolic pathwayin producing pathophysiological changes of DPN, and treatments using aldose reductase inhibitors were found to reverse those changes. Keywords: Polyol pathway; Myo-inositol; Sorbitol; Neurophysiology; Endocrinology. The aim of this short communication oxidized (GSSG) glutathione levels in crude article was to enlighten the role of polyol homogenates of rat sciatic nerve. The study pathway in pathophysiology of diabetic concluded that altered glutathione redox peripheral neuropathy (DPN) through an state played no detectable role in the evidence-informed overview of current pathogenesis of this defect in diabetic literature. peripheral nerve. Calcutt et al[1] measured motor nerve Finegold et al[3] studied the effect of conduction velocity (MNCV), Na(+)-K(+)- polyol pathway blockade with sorbinil, a ATPase activity, polyol-pathway specific inhibitor of aldose reductase, on metabolites, and myo-inositol in sciatic nerve myo-inositol content in acutely nerves from control mice, galactose-fed streptozotocin-diabetic ratswhich (20% wt/wt diet) mice, and galactose-fed completely prevented the fall in nerve myo- mice given the aldose reductase inhibitor inositol.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Review of Nisha Amalaki –An Ayurvedic Formulation of Turmeric and Indian Goose Berry in Diabetes
    wjpmr, 2017,3(9), 101-105 SJIF Impact Factor: 4.103 Review Article Bedarkar. WORLD JOURNAL OF PHARMACEUTICAL World Journal of Pharmaceutical and Medical Research AND MEDICAL RESEARCH ISSN 2455-3301 www.wjpmr.com WJPMR REVIEW OF NISHA AMALAKI –AN AYURVEDIC FORMULATION OF TURMERIC AND INDIAN GOOSE BERRY IN DIABETES Dr. Prashant Bedarkar* Assistant Prof. Dept. of Rasashastra and B.K., IPGT & R. A., Jamnagar, Gujarat, India. *Corresponding Author: Dr. Prashant Bedarkar Assistant Prof. Dept. of Rasashastra and B.K., IPGT & R. A., Jamnagar, Gujarat, India. Article Received on 01/08/2017 Article Revised on 22/08/2017 Article Accepted on 12/09/2017 ABSTRACT Introduction- Nishamalaki or Nisha Amalaki representing various combination formulations of Turmeric (Nisha, Haridra, Curcuma longa L.) and Indian gooseberry (Amalaki, Emblica officinalis Gaertn.) is recommended in Ayurvedic classics, proven efficacious and widely practiced in the management i.e. treatment of Diabetes along with management and prevention of complications of Madhumeha (Diabetes). Aims and objectives-Inspite of many pharmacological, clinical researches of Nishamalaki on Glucose metabolism and Glycemic control, their review is not available, hence present study was conducted. Material and methods- Evidence based online published researches of Nishamalaki on Glucose metabolism and Glycemic control and its efficacy in the management of complications of Diabetes from available databases and search engines were referred for review through. Summary of published researches was systematically arranged, analyzed and presented. Observations and results-Review of online Published original research studies reveals total were found to be 13 in number, comprising of 3 in vitro studies and animal experimental pharmacological researches each and 7 clinical researches.
    [Show full text]
  • Evaluation of Effect of Nishamalaki on STZ and HFHF Diet Induced Diabetic
    DOI: 10.7860/JCDR/2016/21011.8752 Experimental Research Evaluation of Effect of Nishamalaki on STZ and HFHF Diet Induced Diabetic Pharmacology Section Neuropathy in Wistar Rats JAYSHREE SHRIRAM DAWANE1, VIJAYA ANIL PANDIT2, MADHURA SHIRISH KUMAR BHOSALE3, PALLAWI SHASHANK KHATAVKAR4 ABSTRACT Pioglitazone and Epalrestat. Animals received drug treatment Introduction: Diabetic neuropathy is one of the most common for next 12 weeks. Monitoring of Blood Sugar Level (BSL) done complications affecting 50% of diabetic patients. Neuropathic every 15 days and lipid profile at the end. Eddy’s hot plate and pain is the most difficult types of pain to treat. There is no specific tail immersion test performed to assess thermal hyperalgesia treatment for neuropathy. Nishamalaki (NA), combination of and cold allodynia. Walking function test performed to assess Curcuma longa and Emblica officinalis used to treat Diabetes motor function. Mellitus (DM). So, efforts were made to test whether NA is useful Results: Diabetic rats exhibited significant (p<0.001) hyperal- in prevention of diabetic neuropathy. gesia and increased BSL compared to control rats. Dose- Aim: To evaluate the effect of NA on diabetic neuropathy in type dependent improvement was observed in thermal hyperalgesia 2 diabetic wistar rats. & cold allodynia in NA groups. Activity of NA was more than Glibenclamide, Epalrestat and Pioglitazone in high dose and Materials and Methods: Group I (Control) vehicle treated comparable in low dose. Nishamalaki improved lipid profile. consists of 6 rats. Diabetes induced in 36 wistar rats with Streptozotocin (STZ) (35mg/kg) intra-peritoneally followed by Conclusion: Apart from controlling hyperglycaemia and High Fat High Fructose diet.
    [Show full text]
  • Clostridium Difficile Exploits a Host Metabolite Produced During Toxin-Mediated Infection
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.14.426744; this version posted January 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Clostridium difficile exploits a host metabolite produced during toxin-mediated infection 2 3 Kali M. Pruss and Justin L. Sonnenburg* 4 5 Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford 6 CA, USA 94305 7 *Corresponding author address: [email protected] 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.14.426744; this version posted January 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 23 Several enteric pathogens can gain specific metabolic advantages over other members of 24 the microbiota by inducing host pathology and inflammation. The pathogen Clostridium 25 difficile (Cd) is responsible for a toxin-mediated colitis that causes 15,000 deaths in the U.S. 26 yearly1, yet the molecular mechanisms by which Cd benefits from toxin-induced colitis 27 remain understudied. Up to 21% of healthy adults are asymptomatic carriers of toxigenic 28 Cd2, indicating that Cd can persist as part of a healthy microbiota; antibiotic-induced 29 perturbation of the gut ecosystem is associated with transition to toxin-mediated disease.
    [Show full text]
  • Scholars Journal of Medical Case Reports Prolonged Hypoglycemia
    DOI: 10.21276/sjmcr.2017.5.1.9 Scholars Journal of Medical Case Reports ISSN 2347-6559 (Online) Sch J Med Case Rep 2017; 5(1):24-27 ISSN 2347-9507 (Print) ©Scholars Academic and Scientific Publishers (SAS Publishers) (An International Publisher for Academic and Scientific Resources) Prolonged hypoglycemia after an insulin glargine overdose in a patient with type 2 diabetes mellitus Kei Jitsuiki1, Toshihiko Yoshizawa1, Ikuto Takeuchi1, Chikato Hayashi1, Hiromichi Ohsaka1, Kouhei Ishikawa1, Kazuhiko Omori1, Youichi Yanagawa1 1Department of Acute Critical Care Medicine, Shizuoka Hospital, Juntendo University, Japan *Corresponding author Youichi Yanagawa Email: [email protected] Abstract: A fifty-seven-year-old male patient self-administered maximum 300 units of glargine by subcutaneous injection. He was found after being in an unconscious state for approximately 15 hours, and was transferred to a nearby medical facility. He had been taking glargine for type 2 diabetes mellitus. He had been in a depressive state following his retirement. He was diagnosed with prolonged hypoglycemia induced by a suicide attempt and was transported to our hospital by a physician staffed helicopter. On arrival, He was alert and admitted to an intensive care unit where he received a continuous drip infusion with 10% glucose and intermittent 50% glucose injection (40ml) when his blood glucose level fell to <70mg/dl (his blood glucose level was measured every 30 minutes). The patient consumed a 1600 Kcal meal each day. At 36 hours after admission, he no longer showed hypoglycemia and did not require glucose injections. The total amount of glucose required from admission until he left the intensive care unit was 1244 g.
    [Show full text]
  • Aldose Reductase Inhibitors for Diabetic Cataract: a Study of Disclosure Patterns in Patents and Peer Review Papers
    Ophthalmology Research: An International Journal 2(3): 137-149, 2014, Article no. OR.2014.002 SCIENCEDOMAIN international www.sciencedomain.org Aldose Reductase Inhibitors for Diabetic Cataract: A Study of Disclosure Patterns in Patents and Peer Review Papers H. A. M. Mucke1*, E. Mucke1 and P. M. Mucke1 1H. M. Pharma Consultancy, Enenkelstr. 28/32, A-1160 Wien, Austria. Authors’ contributions This work was carried out in collaboration between all authors. Author MHAM designed the study, performed the analysis, and drafted the manuscript. Authors EM and PMM performed data curation and iterative information retrieval. All authors read and approved the final manuscript. Received 29th September 2013 th Original Research Article Accepted 11 December 2013 Published 15th January 2014 ABSTRACT Aims: To investigate, for 13 aldose reductase inhibitors that had been in development for diabetic cataract, whether patent documents could provide earlier dissemination of knowledge to the ophthalmology community than peer review papers. Methodology: Searches for intellectual property disclosures were conducted in our internal database of ophthalmology patent documents, and were supplemented by online searches in the public Espacenet and Google Patents databases. Searches for peer review papers were performed in Pub Med and Google Scholar, and in our internal database of machine-readable ophthalmology publications. Results: For sorbinil, tolrestat, fidarestat and GP-1447 patent documents clearly preempted the peer review literature in terms of data-supported information on potential effectiveness in diabetic cataract, typically by 7-17 months. For alrestatin, zenarestat, zopolrestat, indomethacin, and quercitrin academic journals were clearly first to properly report this therapeutic utility, preempting the corresponding patents by 6 months to several years.
    [Show full text]
  • Ular Basis of KAISER, S
    Heredity 74 (1995) 267—273 Received6May 1994 OThe Genetical Society of Great Britain 1981. The molecular basis of KAISER, S. 1935. The factorsSOMMER, controlling H. 1991. Genetic shape control ofand flower sizedevelopment in Genetic differentiation among populations of by homeotic genes in Antirrhinum majus. Science, 250, Myopus schisticolor (the wood lemming) — LANDE, R. 1981. The minimumSHORE, number J. S. AND BARRETF, of genes S. C. H. 1990. contributing Quantitative genetics of floral characters in homostylous Turnera ulmifolia var, isozyme variation angustifolia Willd. (Turneraceae). Heredity, 64, LANDE, R, 1983. The responseSINNO1F, to e. w.selection 1935. Evidence onfor the major existence of and genes VADIM B. FEDOROVif, RICKARD FREDRIKSSON1: & KARLFREDGA* SINNO'rr, E. w. 1936. A developmental analysis of inherited t/nstitute of Plant and Animal Ecology, Russian Academy of Sciences, 8 March Street 202, Jekaterinburg 620 008, tion on correlated characters.shape Evolution, differences in Cucurbit37, 1210—1226. fruits. Am. Nat., 70, Russia and Department of Genetics, Uppsa/a University, Box 7003, S-75007Uppsala, Sweden LORD, C. M. AND HILL, .i. i'. 1987. Evidence for heterochrony in Toinvestigate genetic differentiation among populations of the wood lemming Myopus schistico!or (eds) Development as an Evolutiona,ySMITH, H. H. 1950. DevelopmentalProcess, restrictions pp. 47—70. on recombina- (Muridae, Rodentia) isozyme variation in 10 populations from three regions, Fennoscandia, Western and Eastern Siberia, was examined. From 20 loci examined, the two most polymorphic MACNAIR, M. R. AND CUMBES,TAKHTAJAN, o. .i. 1989. A. 1976. The Neoteny genetic and the architectureorigin of flowering ones, Idh-1 and Pgi-1, were used in the complete survey.
    [Show full text]
  • Repurposing of Drugs for Triple Negative Breast Cancer: an Overview
    Repurposing of drugs for triple negative breast cancer: an overview Andrea Spini1,2, Sandra Donnini3, Pan Pantziarka4, Sergio Crispino4,5 and Marina Ziche1 1Department of Medicine, Surgery and Neuroscience, University of Siena, Siena 53100, Italy 2Service de Pharmacologie Médicale, INSERM U1219, University of Bordeaux, Bordeaux 33000, France 3Department of Life Sciences, University of Siena, Siena 53100, Italy 4Anticancer Fund, Strombeek Bever 1853, Belgium 5ASSO, Siena, Italy Abstract Breast cancer (BC) is the most frequent cancer among women in the world and it remains a leading cause of cancer death in women globally. Among BCs, triple negative breast cancer (TNBC) is the most aggressive, and for its histochemical and molecular charac- teristics is also the one whose therapeutic opportunities are most limited. The REpur- posing Drugs in Oncology (ReDO) project investigates the potential use of off patent non-cancer drugs as sources of new cancer therapies. Repurposing of old non-cancer drugs, clinically approved, off patent and with known targets into oncological indications, Review offers potentially cheaper effective and safe drugs. In line with this project, this article describes a comprehensive overview of preclinical or clinical evidence of drugs included in the ReDO database and/or PubMed for repurposing as anticancer drugs into TNBC therapeutic treatments. Keywords: triple negative breast cancer, repositioning, non-cancer drug, preclinical studies, clinical studies Background Correspondence to: Marina Ziche Breast cancer (BC) is the most frequent cancer among women in the world. Triple nega- Email: [email protected] tive breast cancer (TNBC) is a type of BC that does not express oestrogen receptors, pro- 2020, :1071 gesterone receptors and epidermal growth factor receptors-2/Neu (HER2) and accounts ecancer 14 https://doi.org/10.3332/ecancer.2020.1071 for the 16% of BCs approximatively [1, 2].
    [Show full text]
  • Global Profiling of Metabolic Adaptation to Hypoxic Stress in Human Glioblastoma Cells
    Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells. Kucharzewska, Paulina; Christianson, Helena; Belting, Mattias Published in: PLoS ONE DOI: 10.1371/journal.pone.0116740 2015 Link to publication Citation for published version (APA): Kucharzewska, P., Christianson, H., & Belting, M. (2015). Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells. PLoS ONE, 10(1), [e0116740]. https://doi.org/10.1371/journal.pone.0116740 Total number of authors: 3 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. LUND UNIVERSITY PO Box 117 221 00 Lund +46 46-222 00 00 Download date: 07. Oct. 2021 RESEARCH ARTICLE Global Profiling of Metabolic Adaptation to Hypoxic Stress in Human Glioblastoma Cells Paulina Kucharzewska1, Helena C.
    [Show full text]
  • A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis And
    A Role for the Polyol Pathway in the Early Neuroretinal Apoptosis and Glial Changes Induced by Diabetes in the Rat Veronica Asnaghi, Chiara Gerhardinger, Todd Hoehn, Abidemi Adeboje, and Mara Lorenzi We tested the hypothesis that the apoptosis of inner Mu¨ ller cells (the glia that share functions with astrocytes retina neurons and increased expression of glial fibril- in the inner retina but span the whole thickness of the lary acidic protein (GFAP) observed in the rat after a retina with their radial processes) (3). In diabetes, Mu¨ ller short duration of diabetes are mediated by polyol path- cells acquire prominent GFAP immunoreactivity through- way activity. Rats with 10 weeks of streptozotocin- out the extension of their processes (4,5), whereas astro- induced diabetes and GHb levels of 16 ؎ 2% (mean ؎ cytes progressively lose GFAP immunoreactivity (6) and SD) showed increased retinal levels of sorbitol and may also decrease in number (7); the levels of GFAP fructose, attenuation of GFAP immunostaining in astro- measured in the whole retina are increased (4,5). cytes, appearance of prominent GFAP expression in The retinal neuroglial abnormalities are observed before Mu¨ ller glial cells, and a fourfold increase in the number of apoptotic neurons when compared with nondiabetic the characteristic lesions of diabetic microangiopathy; rats. The cells undergoing apoptosis were immunoreac- they occur predominantly in the inner retina, where the tive for aldose reductase. Sorbinil, an inhibitor of al- capillaries also reside; and they involve cells that are dose reductase, prevented all abnormalities. Intensive topographically and functionally connected with vessels. insulin treatment also prevented most abnormalities, Understanding their mechanisms and consequences may despite reducing GHb only to 12 ؎ 1%.
    [Show full text]